Brief: Sensorion Announces Publication Of Seliforant Phase 1 Study Data

Sensorion SA

26/09/2018 06:36

Sept 26 (Reuters) - SENSORION SA  ALSEN.PA :
    * SENSORION ANNOUNCES PUBLICATION OF SELIFORANT PHASE 1 STUDY DATA IN THE BRITISH JOURNAL OF
CLINICAL PHARMACOLOGY
    * SELIFORANT WAS WELL TOLERATED, NO SEDATION WAS REPORTED
    * SELIFORANT DEMONSTRATED A PHARMACOKINETIC PROFILE ACCEPTABLE FOR DAILY ORAL DOSING
    * SELIFORANT IS CURRENTLY BEING STUDIED IN AN ONGOING PHASE 2 TRIAL FOR TREATMENT OF ACUTE
UNILATERAL VESTIBULOPATHY
    * SOME DATA ARE EXPECTED AT END OF 2018

Source text for Eikon:  ID:nBw2ZtGhwa 
Further company coverage:  ALSEN.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))